Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2015 | Retinal Disorders

Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey

Authors: Huseyin Yetik, Murat Gunay, Sarkis Sirop, Ziya Salihoglu

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2015

Abstract

Purpose

To study the efficacy of intravitreal bevacizumab (IVB) injection as a single treatment for retinopathy of prematurity (ROP).

Methods

This was a prospective interventional case series study performed in a clinical practice setting; a total of 122 patients including prethreshold (type 1) (n = 79, 152 eyes, six unilateral), threshold (n = 12, 24 eyes), and aggressive posterior (APROP) (n = 31, 62 eyes); cases were included without any randomization or masking. A total of 253 IVB injections, 238 in the first session, 11 in the second session, and four in the third session were performed, and followed up for a mean of 89.155 ± 4.277 (range 82 to 105) weeks of postmenstrual age (PMA). Regression of ROP, maturation of the retina, and associated complications were evaluated.

Results

Total regression was achieved in 227/238 eyes (95.4 %) after the first dose injection. The remaining 11 received a second injection, after which an additional seven (234/238; 98.2 %) regressed; after the third injection, the remaining 4 (238/238; 100 %) regressed. Complete retinal vascular maturation was achieved without any significant complications in all of the cases.

Conclusions

IVB injection as monotherapy seems to be a very effective treatment modality for ROP. Based on timely intervention, IVB as a single treatment modality can salvage almost all ROP cases before stage 4.

Available only for authorised users

Gilbert C, Rahi J, Eckstein M, O’Sullivan J, Foster A (1997) Retinopathy of prematurity in middle-income countries. Lancet 350(9070):12–14CrossRefPubMed

Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol 106(4):471–479CrossRef

Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity:results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684–1694CrossRefPubMed

International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123(7):991–999CrossRef

Morizane H (1976) Initial sign and clinical course of the most severe form of acute proliferative retrolental fibroplasias (type 1) [in Japanese]. Nippon Ganka Gakkai Zasshi 80(1):54–61PubMed

O’Keefe M, Lanigan B, Long VW (2003) Outcome of zone I retinopathy of prematurity. Acta Ophthalmol Scand 81(6):614–616CrossRefPubMed

Onofrey CB, Feuer WJ, Flynn JT (2001) The outcome of retinopathy of prematurity: screening for retinopathy of prematurity using an outcome predictive program. Ophthalmology 108(1):27–35CrossRefPubMed

Hatsukawa Y, Ueki N, Yamagishi T, Kiytajima H (2005) The effect of early treatment at the initial stage 3 moderate phase of retinopathy of prematurity on severe retinal changes. Jpn J Ophthalmol 49(5):391–396CrossRefPubMed

Jalali S, Kesarwani S, Hussain A (2011) Outcomes of a protocol-based management of zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program Report Number 2. Am J Ophthalmol 151(4):719–724CrossRefPubMed

10.

Yuka S, Fujino T, Hatsukawa Y (2008) Progression and timing of treatment of zone 1 retinopathy of prematurity. Am J Ophthalmol 146(3):369–374CrossRef

11.

Kychenthal A, Dorta P, Katz X (2006) Zone 1 retinopathy of prematurity. Retina 26(7):11–15CrossRef

12.

González Viejo I, Ferrer Novella C, Pueyo RV (2011) Use of anti-VEGF (anti-vascular endothelial growth factor) in retinopathy of prematurity (ROP). Arch Soc Esp Oftalmol 86(7):207–208CrossRefPubMed

13.

Romagnoli C (2009) Risk factors and growth factors in ROP. Early Hum Dev 85(10):79–82CrossRef

14.

Alon T, Hemo I, Itin A et al (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024–1028CrossRefPubMed

15.

Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK (2011) Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 118(1):176–183CrossRefPubMed

16.

Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone 1 retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727–1730CrossRefPubMed

17.

Mintz-Hittner HA, Kuffel RR (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone 1 or posterior zone 2. Retina 28(6):831–838CrossRefPubMed

18.

Altınsoy HI, Mutlu FM, Gungor R, Sarici SU (2010) Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 9:1–5

19.

Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL (2010) Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 14(1):6–10CrossRefPubMed

20.

Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab (Avastin) for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603–615CrossRef

21.

Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 248(9):1257–1262CrossRefPubMed

22.

Mintz-Hittner HA (2012) Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev 88(12):937–941CrossRefPubMed

23.

Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB (2013) Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155(6):1119–1124CrossRefPubMed

24.

Spandau U, Tomic Z, Ewald U et al (2013) Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol 91(2):170–175CrossRefPubMed

25.

Nazari H, Modarres M, Parvaresh MM et al (2010) Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248(12):1713–1718CrossRefPubMed

26.

Lalwani GA, Berrocal AM, Murray TG et al (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28(3):13–18CrossRef

27.

Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists (2013) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131(1):189–195, originally published online December 31, 2012. DOI: 10.1542/peds.2012-2996 CrossRefPubMed

28.

Kashani AH, Drenser KA, Capone Jr A (2014) Retinopathy of prematurity. In: Yanoff M, Duker JS (eds) Ophthalmology, 4th Edition. Elsevier Saunders, pp 535–540

29.

http://www.turkstat.gov.tr/PreHaberBultenleri.do;jsessionid=PJhDTnPKfGBrjQQGqRstp6NpTt9GpvCTMBFGL1 mQJqnr2QWJp2FJ!-568420742?id = 16048 Accessed 20 Aug 2014

30.

Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832):2162–2172CrossRefPubMed

Title: Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey
Authors: Huseyin Yetik
Murat Gunay
Sarkis Sirop
Ziya Salihoglu
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2015
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-014-2867-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity — 27 month follow-up results from Turkey

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

Quantifying silicone oil emulsification in patients: are we only seeing the tip of the iceberg?

Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients

Dexamethasone intravitreal implant (Ozurdex®) for pediatric uveitis

Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm

Analysis of the ganglion cell layer and photoreceptor layer using optical coherence tomography after idiopathic epiretinal membrane surgery

Strabismus in infants following congenital cataract surgery